MedTrace Logo

NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer

NCT03862144 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-03-05

No results posted yet for this study

Summary

This study evaluates if the activity of one-day of NEPA plus dexamethasone, to prevent chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant AC-based chemotherapy, is maintained during all the chemotherapy cycle treatment (maximum 4 cycles).

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG

Netupitant/Palonosetron

Sponsors & Collaborators

  • Consorzio Oncotech

    lead OTHER

Principal Investigators

  • Michelino De Laurentiis, MD, PhD · National Cancer Institute "Fondazione Pascale", Naples

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-12
Primary Completion
2017-04-03
Completion
2017-04-03

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03862144 on ClinicalTrials.gov